These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25906745)

  • 1. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.
    Mancarella C; Casanova-Salas I; Calatrava A; Ventura S; Garofalo C; Rubio-Briones J; Magistroni V; Manara MC; López-Guerrero JA; Scotlandi K
    Oncotarget; 2015 Jun; 6(18):16611-22. PubMed ID: 25906745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
    Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
    BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
    Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
    Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
    Geybels MS; McCloskey KD; Mills IG; Stanford JL
    Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.
    Magistroni V; Mologni L; Sanselicio S; Reid JF; Redaelli S; Piazza R; Viltadi M; Bovo G; Strada G; Grasso M; Gariboldi M; Gambacorti-Passerini C
    PLoS One; 2011; 6(11):e28162. PubMed ID: 22140532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.
    Wright JL; Chéry L; Holt S; Lin DW; Luedeke M; Rinckleb AE; Maier C; Stanford JL
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):53-6. PubMed ID: 26503111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
    Kron KJ; Murison A; Zhou S; Huang V; Yamaguchi TN; Shiah YJ; Fraser M; van der Kwast T; Boutros PC; Bristow RG; Lupien M
    Nat Genet; 2017 Sep; 49(9):1336-1345. PubMed ID: 28783165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer.
    Tolkach Y; Zarbl R; Bauer S; Ritter M; Ellinger J; Hauser S; Hüser L; Klauck SM; Altevogt P; Sültmann H; Dietrich D; Kristiansen G
    Am J Pathol; 2021 Apr; 191(4):618-630. PubMed ID: 33485866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG protein expression as a biomarker of prostate cancer.
    Falzarano SM; Magi-Galluzzi C
    Biomark Med; 2013 Dec; 7(6):851-65. PubMed ID: 24266818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
    Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.